Obesity as a risk factor for Clostridium difficile infection
- PMID: 23645850
- DOI: 10.1093/cid/cit280
Obesity as a risk factor for Clostridium difficile infection
Abstract
Background: Obesity and Clostridium difficile infection (CDI) are both related to an increased Firmicutes/Bacteroidetes ratio in the intestinal microbiota. However, an association between obesity and CDI is unknown. We aimed to assess the association between obesity and CDI in hospitalized patients.
Methods: We conducted a retrospective case-control study. From January to December 2011, all consecutive patients hospitalized with CDI, in 2 internal medical departments in 2 hospitals, were included. Patients with CDI were compared to hospitalized patients without diarrhea, during the same period and in the same departments, and matched by age, sex, Charlson score, length of hospitalization, and antibiotic use during the last 3 months.
Results: Of the 6300 patients hospitalized, 178 were diagnosed with CDI. CDI prevalence was 2.8% (178/6300). Thirty patients were excluded from the study. The 148 cases with CDI were compared to 148 hospitalized controls. Mean body mass index (BMI) in the CDI group was 33.6 (SD, 4.3) versus 28.9 (SD, 5.4) in the control group (P = .001). The multivariable model of conditional logistic regression for matched pairs showed that a history of intra-abdominal surgery (odds ratio [OR] = 2.865; 95% confidence interval [CI], 1.26-6.52) and a high BMI value (OR = 1.196 per 1-unit increase in the BMI scale; 95% CI, 1.12-1.27) were the only variables found to be significantly associated with CDI.
Conclusions: Our findings suggest that obesity is associated with the risk of CDI. Further studies are needed to reveal the exact mechanisms underlying this association.
Keywords: BMI; Bacteroidetes; Clostridium difficile; Firmicutes; microbiota.
Similar articles
-
Do statins protect against the development of Clostridium difficile-associated diarrhoea?J Antimicrob Chemother. 2013 Aug;68(8):1889-93. doi: 10.1093/jac/dkt101. Epub 2013 Apr 5. J Antimicrob Chemother. 2013. PMID: 23563740
-
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.J Antimicrob Chemother. 2012 Mar;67(3):742-8. doi: 10.1093/jac/dkr508. Epub 2011 Dec 6. J Antimicrob Chemother. 2012. PMID: 22146873
-
Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study.Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1201-5. doi: 10.1007/s10096-015-2348-3. Epub 2015 Feb 17. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25686730
-
Clostridium difficile Infection in travelers--a neglected pathogen?J Travel Med. 2013 Jan-Feb;20(1):37-43. doi: 10.1111/j.1708-8305.2012.00676.x. Epub 2012 Dec 4. J Travel Med. 2013. PMID: 23279229 Review.
-
Community-associated Clostridium difficile infection and antibiotics: a meta-analysis.J Antimicrob Chemother. 2013 Sep;68(9):1951-61. doi: 10.1093/jac/dkt129. Epub 2013 Apr 25. J Antimicrob Chemother. 2013. PMID: 23620467 Review.
Cited by
-
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29. Clin Microbiol Rev. 2024. PMID: 38421181 Review.
-
Multi-kingdom microbial signatures in excess body weight colorectal cancer based on global metagenomic analysis.Commun Biol. 2024 Jan 5;7(1):24. doi: 10.1038/s42003-023-05714-0. Commun Biol. 2024. PMID: 38182885 Free PMC article.
-
The gut mucin-microbiota interactions: a missing key to optimizing endurance performance.Front Physiol. 2023 Nov 22;14:1284423. doi: 10.3389/fphys.2023.1284423. eCollection 2023. Front Physiol. 2023. PMID: 38074323 Free PMC article. Review.
-
Effect of diet on pathogen performance in the microbiome.Microbiome Res Rep. 2022 Mar 26;1(2):13. doi: 10.20517/mrr.2021.10. eCollection 2022. Microbiome Res Rep. 2022. PMID: 38045644 Free PMC article. Review.
-
Clostridioides difficile Infection: Landscape and Microbiome Therapeutics.Gastroenterol Hepatol (N Y). 2023 Jun;19(6):319-328. Gastroenterol Hepatol (N Y). 2023. PMID: 37706187 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
